Sorafenib for Metastatic Prostate Cancer
Name of the Trial
Why This Trial Is Important
Many new drugs are currently being tested for the treatment of metastatic, androgen-independent prostate cancer. Sorafenib (Nexavar) is a type of anticancer drug that belongs to a class of drugs called small-molecule inhibitors. Small-molecule inhibitors block the activity of proteins in cancer cells that help promote cell division and survival.
Sorafenib inhibits the activity of at least three cancer-cell proteins involved in cell signaling - the transmission of information within a cell or between cells. The inhibition of multiple signaling proteins blocks both tumor-cell division and the growth of new blood vessels (angiogenesis) that feed the tumor.
"In the laboratory, sorafenib had activity against both signal transduction and angiogenesis in prostate cancer," explained Dr. Dahut. "We believe that angiogenesis is an important target in prostate cancer. Patients who have more vascular tumors at the time of initial diagnosis are more likely to eventually develop metastatic disease."
Who Can Join This Trial
Study Sites and Contact Information
An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.